


CLAIMS

1. A compound of Formula (I):



Formula (I)

Wherein:

R^1 , R^2 , R^3 , R^4 , R^5 , R^{6a} , R^{6b} , X and Y are as described herein:

X is CH or N;

Y is C, CH or N;

n is 1 or 2;

--- is a single or a double bond, provided that if Y is C, then == represents a double bond;

When Y is N or CH and == represents a double bond, R^2 is absent;

R^1 is selected from H, C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, C_5 - C_8 heterocycloalkyl, aryl, arylalkyl, heteroaryl, $C(O)OR^7$, and $S(O)_2R^7$, wherein C_1 - C_6 alkyl, C_5 - C_8 heterocycloalkyl, aryl, arylalkyl, or heteroaryl is optionally substituted with one or more halo, hydroxy, or OR^7 ;

When Y is C and == represents a double bond, or when Y is CH or N and --- represents a single bond, then,

R^2 is selected from H, halo, CF_3 , C_1 - C_4 alkyl and aryl, wherein the C_1 - C_4 alkyl or aryl is optionally substituted with one or more halo, amino, hydroxy, alkoxy, or haloalkyl;

R^3 is selected from H, halo, $C(O)NR^7R^7$, $C(O)R^7$, $S(O)_mR^7$, and $S(O)_mNR^7R^7$, wherein each m is 1 or 2;

- R^4 is selected from H, halo, C_1 - C_6 alkyl, and C_3 - C_7 cycloalkyl, wherein the C_1 - C_6 alkyl, or C_3 - C_7 cycloalkyl is optionally substituted with one or more halo, amino, hydroxy, alkoxy, or haloalkyl;
- R^5 is selected from H, halo, C_1 - C_6 alkyl, and C_3 - C_7 cycloalkyl, wherein C_1 - C_6 alkyl or
5 C_3 - C_7 cycloalkyl is optionally and independently substituted with one or more halo, alkoxy, or haloalkyl;
- R^{6a} is selected from H, halo, hydroxy, CN, CH_2OH , NH_2 , C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, C_6 - C_{10} aryl, heteroaryl, OR^7 , NR^7R^7 , NHR^7 , and $NHC(O)R^7$;
- R^{6b} is selected from H, CH_2OH , CH_2NH_2 , and C_1 - C_6 alkyl;
- 10 R^7 is independently selected from C_1 - C_6 alkyl, C_3 - C_6 alkenyl, C_3 - C_6 alkynyl, C_3 - C_7 cycloalkyl, aryl, aryl(C_1 - C_4)alkyl, haloalkyl, heteroaryl, and heterocycloalkyl, wherein the C_1 - C_6 alkyl, C_3 - C_6 alkenyl, C_3 - C_6 alkynyl, C_3 - C_7 cycloalkyl, aryl, aryl(C_1 - C_4)alkyl, haloalkyl, heteroaryl, or heterocycloalkyl is optionally and independently substituted with one or more substituents
15 selected from aryl, cycloalkyl, heteroaryl, heterocycloalkyl, alkyl, halo, amino, and hydroxy;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein R^1 is selected from H, methyl, ethyl,
20 propyl, isopropyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, 2-hydroxyethyl, 2-methoxyethyl, 2,2,2-trifluoroethyl, 2-fluoroethyl, ethylcarboxyl, methylsulfonyl, arylalkyl, or cyclopropylmethyl.
3. The compound of claim 1, wherein Y is C or CH.
4. The compound of claim 1, wherein R^2 is H, halo, CF_3 , C_1 - C_4 alkyl or aryl,
25 wherein the C_1 - C_4 alkyl or aryl is optionally substituted with one or more halo, alkoxy, or haloalkyl.
5. The compound of claim 1, wherein Y is N.
6. The compound of claim 1, wherein R^3 is H, halo, $C(O)NR^7R^7$, $C(O)R^7$, $S(O)_mR^7$, $S(O)_mNR^7R^7$, wherein each m is 1 or 2.
- 30 7. The compound of claim 6, wherein R^3 is selected from acetyl, propionyl, cyclopropyl carbonyl, fluoromethyl carbonyl, difluoromethyl carbonyl,

trifluoromethyl carbonyl, methanesulfonyl, ethanesulfonyl, cyclopropanesulfonyl, benzenesulfonyl, *p*-toluenesulfonyl, *N,N*-dimethylaminocarbonyl, morpholinylcarbonyl, or pyrrolidinylcarbonyl.

8. The compound of claim 1, wherein R⁴ is selected from H, F, Cl, Br, CH₃, CF₃, ethyl, cyclopropyl, or cyclobutyl.

9. The compound of claim 1, wherein R⁵ is selected from H, Cl, Br, CH₃, CF₃, ethyl, isopropyl, cyclopropyl, cyclobutyl, or phenyl.

10. The compound of claim 1, wherein R^{6a} is selected from halo, hydroxy, CN, CH₂OH, NH₂, C₁-C₆alkyl, C₃-C₇cycloalkyl, C₆-C₁₀aryl, heteroaryl, OR⁷, NR⁷R⁷, NHR⁷, and NHC(O)R⁷.

11. A compound selected from the group consisting of

(S)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)methanone;

(S)-1-(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)-2-methylpropan-1-one;

(S)-2,2,2-trifluoro-1-(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)ethanone;

(S)-2,2-difluoro-1-(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)ethanone;

(S)-ethyl 3-acetyl-5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1H-indole-1-carboxylate;

(S)-cyclopropyl(1-ethyl-5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)methanone;

(S)-2,2,2-trifluoro-1-(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)ethanone;

(S)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-isopropyl-1H-indol-3-yl)methanone;


(S)-1-(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)ethanone;

(R)-2,2-difluoro-1-(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)ethanone;

- (R)-cyclopropyl(1-ethyl-5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)methanone;
(S)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)methanone;
5 cyclopropyl(1-ethyl-5-(4-(4-((4-hydroxy-4-methylisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)methanone;
cyclopropyl(5-(4-(4-((4-hydroxy-4-methylisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)methanone;
(S)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-(2,2,2-trifluoroethyl)-1H-indol-3-yl)methanone;
10 cyclopropyl(5-(4-(4-((4-hydroxy-4-methylisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-(2,2,2-trifluoroethyl)-1H-indol-3-yl)methanone;
cyclopropyl(5-(4-(4-((4-hydroxy-4-methylisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-(2,2,2-trifluoroethyl)-1H-indol-3-yl)methanone;
15 (S)-1-(5-(5-chloro-4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)-2,2,2-trifluoroethanone;
(S)-2,2,2-trifluoro-1-(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)-5-methylpyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)ethanone;
20 (S)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)-5-methylpyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)methanone;
(S)-cyclopropyl(1-ethyl-5-(5-fluoro-4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)methanone;
25 (S)-cyclopropyl(1-ethyl-5-(5-fluoro-4-(3-((4-hydroxyisoxazolidin-2-yl)methyl)-4-methyl-1H-pyrrol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)methanone;
(S)-cyclopropyl(1-ethyl-5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)-5-methylpyrimidin-2-ylamino)-1H-indol-3-yl)methanone;
30 (S)-cyclopropyl(1-ethyl-5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)-5-methylpyrimidin-2-ylamino)-1H-indol-3-yl)methanone;


- (S)-cyclopropyl(1-(2-fluoroethyl)-5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)methanone;
- 5 cyclopropyl(1-(2-fluoroethyl)-5-(4-(4-(((S)-4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)indolin-3-yl)methanone;
- (S)-cyclopropyl(5-(4-(3-cyclopropyl-4-((4-hydroxyisoxazolidin-2-yl)methyl)-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-ethyl-1H-indol-3-yl)methanone;
- 10 (S)-2-((3-methyl-1-(2-(1-methyl-3-(methylsulfonyl)-1H-indazol-5-ylamino)pyrimidin-4-yl)-1H-pyrazol-4-yl)methyl)isoxazolidin-4-ol;
- (S)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-(methylsulfonyl)-1H-indol-3-yl)methanone;
- 15 (S)-cyclopropyl(1-ethyl-5-(4-(3-((4-hydroxyisoxazolidin-2-yl)methyl)-4-methyl-1H-pyrrol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)methanone;
- (S)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)methanone;
- (S)-2-((1-(2-(3-chloro-1,2-dimethyl-1H-indol-5-ylamino)pyrimidin-4-yl)-3-methyl-1H-pyrazol-4-yl)methyl)isoxazolidin-4-ol;
- 20 (S)-cyclopropyl(1-(2-fluoroethyl)-5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)methanone;
- (S)-cyclopropyl(1-(2,2-difluoroethyl)-5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)methanone;
- and
- 25 (S)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-(2,2,2-trifluoroethyl)-1H-indol-3-yl)methanone;
- or a pharmaceutically acceptable salt thereof.
- 30 12. A pharmaceutical formulation comprising a compound of claim 1, in combination with a pharmaceutically acceptable carrier, diluent, or excipient.
13. A process for preparing a compound of Formula (I) according to claim 1, the process comprising:

- viii. reacting a compound of formula (a) with a compound of formula (b) in a first organic solvent in the presence of a first base to give a compound of formula (c);
- 5 ix. reacting the compound of formula (c) with an aniline derivative of formula (d) in the presence of a second base, a ligand and a palladium catalyst in a second solvent to give a compound of formula (e);
- x. reacting the compound of formula (e) with an amine derivative (f) in a third organic solvent in the presence of reducing agent such as
- 10 NaBH(OAc)₃ to give a compound of Formula I;
- xi. reacting the compound of formula (c) with an amine derivative (f) in a fourth organic solvent in the presence of reducing agent such as NaBH(OAc)₃ to give a compound of formula (g);
- xii. reacting the compound of formula (g) with an aniline derivative formula (d)
- 15 in the presence of a second base and a palladium catalyst to give a compound of Formula I;
- or the compound of formula (e) is prepared by the following steps:
- xiii. reacting a compound of formula (h) with a compound of formula (i) in the presence of a first base in a second organic solvent to give a compound of
- 20 formula (j);
- xiv. reacting the compound of formula (j) with a compound of formula (b) in a second organic solvent in the presence of a first base to give a compound of formula (e);




wherein: R^1 , R^2 , R^3 , R^4 , R^5 , R^{6a} , R^{6b} , n , X and Y are described in claim 1.

- 5 14. A method for preparing a compound of claim 1, the method comprising reacting a compound of formula (g)



in which R^4 , R^5 , R^{6a} , R^{6b} , n and X are as defined in claim 1, with an aniline derivative of formula (d)



in which R^1 , R^2 , R^3 and Y are as defined in claim 1, in the presence of a base and a palladium catalyst under conditions such that a compound of Formula (I) is prepared.

15 15. Use of a compound or pharmaceutically acceptable salt thereof as defined in claim 1 for preparing a medicament for the treatment of diseases which can be treated by inhibition of the SYK enzyme.

16. A compound or pharmaceutically acceptable salt thereof of claim 1, for use in the treatment of an autoimmune condition, the inflammatory diseases and/or allergic disorders such as systemic lupus erythematosus (SLE), discoid (cutaneous) lupus, Sjorgens syndrome, Wegners granulomatosis and other vasculitides, idiopathic thrombocytopenic purpura, giant cell arteriosis, glomerulonephritis, chronic transplant rejection, chronic obstructive pulmonary disease, adult respiratory distress syndrome, asthma, severe asthma, ulcerative colitis, Crohn's disease, bronchitis, conjunctivitis, psoriasis, scleroderma, (contact and allergic) dermatitis, allergy, (allergic) rhinitis, 15 allergic rhinoconjunctivitis, autoimmune bullous conditions including pemphigus and pemphigoid, mastocytosis, anaphylaxis, chronic (spontaneous) urticaria, Berger's disease, Evans's syndrome, granulocytopenia, Goodpasture's syndrome, hepatitis, Henoch-Schonlein purpura, multiple sclerosis, immunohaemolytic anaemia, autoimmune haemolytic anemia, Kawasaki syndrome.

20 17. A compound or pharmaceutically acceptable salt thereof of claim 1, for use in the treatment of rheumatoid arthritis and osteoporosis, osteolytic diseases and osteopenia.


18. A compound or pharmaceutically acceptable salt thereof of claim 1, for use in the treatment of hematologic malignancies, particularly Non-Hodgkin's Lymphomas including follicular (FL), mantle cell, capsule cell lymphoma, neutropenia, small 25 lymphocytic lymphoma, chronic lymphocytic lymphoma, Burkitt and diffuse large B cell lymphomas and T-cell lymphoma.

19. A method for treating a condition selected from an autoimmune condition, an inflammatory disease, or an allergic disorder, the method comprising administering to 30 a patient in need of such treatment an effective amount of a compound or pharmaceutically acceptable salt thereof of claim 1.

20. The method of claim 19, wherein the condition is systemic lupus erythematosus (SLE), discoid (cutaneous) lupus, Sjorgens syndrome, Wegners granulomatosis and other vasculitides, idiopathic thrombocytopenic purpura, giant cell arteriosis, glomerulonephritis, chronic transplant rejection, chronic obstructive pulmonary disease, adult respiratory distress syndrome, asthma, severe asthma, ulcerative colitis, Crohn's disease, bronchitis, conjunctivitis, psoriasis, scleroderma, (contact and allergic) dermatitis, allergy, (allergic) rhinitis, allergic rhinoconjunctivitis, pemphigus, pemphigoid, mastocytosis, anaphylaxis, chronic (spontaneous) urticaria, Berger's disease, Evans's syndrome, granulocytopenia, Goodpasture's syndrome, hepatitis, Henoch-Schonlein purpura, multiple sclerosis, immunohaemolytic anaemia, autoimmune haemolytic anemia, or Kawasaki syndrome.
21. The method of claim 19, wherein said compound is administered singly or in combination with one or more additional therapeutic agents.
22. The method of claim 19 wherein said compound is administered via intravenous administration, subcutaneous administration, inhalation, oral administration, rectal administration, parenteral, intravitreal administration, intramuscular administration, intranasal administration, dermal administration, topical administration, optic administration, ophthalmic administration, buccal administration, tracheal administration, bronchial administration, or sublingual administration.
23. A method for treating a heme malignancy, the method comprising administering to a patient in need thereof an effective amount of a compound or pharmaceutically acceptable salt thereof of claim 1.
24. The method of claim 23, wherein the heme malignancy is selected from the group consisting of Non-Hodgkin's Lymphomas including follicular (FL), mantle cell, capsule cell lymphoma, neutropenia, small lymphocytic lymphoma, chronic lymphocytic lymphoma, Burkitt and diffuse large B cell lymphomas and T-cell lymphoma.

CLAIMS

1. A compound of Formula (I):



Formula (I)

Wherein:

R^1 , R^2 , R^3 , R^4 , R^5 , R^{6a} , R^{6b} , X and Y are as described herein:

X is CH or N;

Y is C, CH or N;

n is 1 or 2;

==== is a single or a double bond, provided that if Y is C, then === represents a double bond;

When Y is N or CH and === represents a double bond, R^2 is absent;

R^1 is selected from H, C_1 - C_6 alkyl, C_3 - C_7 cycloalkyl, C_5 - C_8 heterocycloalkyl, aryl, arylalkyl, heteroaryl, $C(O)OR^7$, and $S(O)_2R^7$, wherein C_1 - C_6 alkyl, C_5 - C_8 heterocycloalkyl, aryl, arylalkyl, or heteroaryl is optionally substituted with one or more halo, hydroxy, or OR^7 ;

When Y is C and === represents a double bond, or when Y is CH or N and === represents a single bond, then,

R^2 is selected from H, halo, CF_3 , C_1 - C_4 alkyl and aryl, wherein the C_1 - C_4 alkyl or aryl is optionally substituted with one or more halo, amino, hydroxy, alkoxy, or haloalkyl;

R^3 is selected from H, halo, $C(O)NR^7R^7$, $C(O)R^7$, $S(O)_mR^7$, and $S(O)_mNR^7R^7$, wherein each m is 1 or 2;

R⁴ is selected from H, halo, C₁-C₆alkyl, and C₃-C₇cycloalkyl, wherein the C₁-C₆alkyl, or C₃-C₇cycloalkyl is optionally substituted with one or more halo, amino, hydroxy, alkoxy, or haloalkyl;

R⁵ is selected from H, halo, C₁-C₆alkyl, and C₃-C₇cycloalkyl, wherein C₁-C₆alkyl or C₃-C₇cycloalkyl is optionally and independently substituted with one or more halo, alkoxy, or haloalkyl;

R^{6a} is selected from H, halo, hydroxy, CN, CH₂OH, NH₂, C₁-C₆alkyl, C₃-C₇cycloalkyl, C₆-C₁₀aryl, heteroaryl, OR⁷, NR⁷R⁷, NHR⁷, and NHC(O)R⁷;

R^{6b} is selected from H, CH₂OH, CH₂NH₂, and C₁-C₆alkyl;

R⁷ is independently selected from C₁-C₆alkyl, C₃-C₆alkenyl, C₃-C₆alkynyl, C₃-C₇cycloalkyl, aryl, aryl(C₁-C₄)alkyl, haloalkyl, heteroaryl, and heterocycloalkyl, wherein the C₁-C₆alkyl, C₃-C₆alkenyl, C₃-C₆alkynyl, C₃-C₇cycloalkyl, aryl, aryl(C₁-C₄)alkyl, haloalkyl, heteroaryl, or heterocycloalkyl is optionally and independently substituted with one or more substituents selected from aryl, cycloalkyl, heteroaryl, heterocycloalkyl, alkyl, halo, amino, and hydroxy;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, wherein R¹ is selected from H, methyl, ethyl, propyl, isopropyl, butyl, cyclopropyl, cyclobutyl, cyclopentyl, 2-hydroxyethyl, 2-methoxyethyl, 2,2,2-trifluoroethyl, 2-fluoroethyl, ethylcarboxyl, methylsulfonyl, arylalkyl, or cyclopropylmethyl.
3. The compound of claim 1, wherein Y is C or CH.
4. The compound of claim 1, wherein R² is H, halo, CF₃, C₁-C₄alkyl or aryl, wherein the C₁-C₄alkyl or aryl is optionally substituted with one or more halo, alkoxy, or haloalkyl.
5. The compound of claim 1, wherein Y is N.
6. The compound of claim 1, wherein R³ is H, halo, C(O)NR⁷R⁷, C(O)R⁷, S(O)_mR⁷, S(O)_mNR⁷R⁷, wherein each m is 1 or 2.
7. The compound of claim 6, wherein R³ is selected from acetyl, propionyl, cyclopropyl carbonyl, fluoromethyl carbonyl, difluoromethyl carbonyl, trifluoromethyl carbonyl,

methanesulfonyl, ethanesulfonyl, cyclopropanesulfonyl, benzenesulfonyl, *p*-toluenesulfonyl, *N,N*-dimethylaminocarbonyl, morpholinylcarbonyl, or pyrrolidinylcarbonyl.

8. The compound of claim 1, wherein R⁴ is selected from H, F, Cl, Br, CH₃, CF₃, ethyl, cyclopropyl, or cyclobutyl.

9. The compound of claim 1, wherein R⁵ is selected from H, Cl, Br, CH₃, CF₃, ethyl, isopropyl, cyclopropyl, cyclobutyl, or phenyl.

10. The compound of claim 1, wherein R^{6a} is selected from halo, hydroxy, CN, CH₂OH, NH₂, C₁-C₆alkyl, C₃-C₇cycloalkyl, C₆-C₁₀aryl, heteroaryl, OR⁷, NR⁷R⁷, NHR⁷, and NHC(O)R⁷.

11. A compound selected from the group consisting of

(S)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)methanone;

(S)-1-(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)-2-methylpropan-1-one;

(S)-2,2,2-trifluoro-1-(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)ethanone;

(S)-2,2-difluoro-1-(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)ethanone;

(S)-ethyl 3-acetyl-5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1H-indole-1-carboxylate;

(S)-cyclopropyl(1-ethyl-5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)methanone;

(S)-2,2,2-trifluoro-1-(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)ethanone;

(S)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-isopropyl-1H-indol-3-yl)methanone;

(S)-1-(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)ethanone;

(R)-2,2-difluoro-1-(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)ethanone;

(R)-cyclopropyl(1-ethyl-5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)methanone;

(S)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)methanone;

cyclopropyl(1-ethyl-5-(4-(4-((4-hydroxy-4-methylisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)methanone;

cyclopropyl(5-(4-(4-((4-hydroxy-4-methylisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)methanone;

(S)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-(2,2,2-trifluoroethyl)-1H-indol-3-yl)methanone;

cyclopropyl(5-(4-(4-((4-hydroxy-4-methylisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-(2,2,2-trifluoroethyl)-1H-indol-3-yl)methanone;

(S)-1-(5-(5-chloro-4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)-2,2,2-trifluoroethanone;

(S)-2,2,2-trifluoro-1-(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)-5-methylpyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)ethanone;

(S)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)-5-methylpyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)methanone;

(S)-cyclopropyl(1-ethyl-5-(5-fluoro-4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)methanone;

(S)-cyclopropyl(1-ethyl-5-(5-fluoro-4-(3-((4-hydroxyisoxazolidin-2-yl)methyl)-4-methyl-1H-pyrrol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)methanone;

(S)-cyclopropyl(1-ethyl-5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)-5-methylpyrimidin-2-ylamino)-1H-indol-3-yl)methanone;

(S)-cyclopropyl(1-(2-fluoroethyl)-5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)methanone;

cyclopropyl(1-(2-fluoroethyl)-5-(4-(4-(((S)-4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)indolin-3-yl)methanone;

(S)-cyclopropyl(5-(4-(3-cyclopropyl-4-((4-hydroxyisoxazolidin-2-yl)methyl)-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-ethyl-1H-indol-3-yl)methanone;

(S)-2-((3-methyl-1-(2-(1-methyl-3-(methylsulfonyl)-1H-indazol-5-ylamino)pyrimidin-4-yl)-1H-pyrazol-4-yl)methyl)isoxazolidin-4-ol;

(S)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-3-methyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-(methylsulfonyl)-1H-indol-3-yl)methanone;

(S)-cyclopropyl(1-ethyl-5-(4-(3-((4-hydroxyisoxazolidin-2-yl)methyl)-4-methyl-1H-pyrrol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)methanone;

(S)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-methyl-1H-indol-3-yl)methanone;

(S)-2-((1-(2-(3-chloro-1,2-dimethyl-1H-indol-5-ylamino)pyrimidin-4-yl)-3-methyl-1H-pyrazol-4-yl)methyl)isoxazolidin-4-ol;

(S)-cyclopropyl(1-(2-fluoroethyl)-5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)methanone;


(S)-cyclopropyl(1-(2,2-difluoroethyl)-5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1H-indol-3-yl)methanone; and

(S)-cyclopropyl(5-(4-(4-((4-hydroxyisoxazolidin-2-yl)methyl)-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-1-(2,2,2-trifluoroethyl)-1H-indol-3-yl)methanone;

or a pharmaceutically acceptable salt thereof.


12. A pharmaceutical formulation comprising a compound of claim 1, in combination with a pharmaceutically acceptable carrier, diluent, or excipient.
13. A process for preparing a compound of Formula (I) according to claim 1, the process comprising:
 - i. reacting a compound of formula (a) with a compound of formula (b) in a first organic solvent in the presence of a first base to give a compound of formula (c);
 - ii. reacting the compound of formula (c) with an aniline derivative of formula (d) in the presence of a second base, a ligand and a palladium catalyst in a second solvent to give a compound of formula (e);

- iii. reacting the compound of formula (e) with an amine derivative (f) in a third organic solvent in the presence of reducing agent such as $\text{NaBH}(\text{OAc})_3$ to give a compound of Formula I;
- iv. reacting the compound of formula (c) with an amine derivative (f) in a fourth organic solvent in the presence of reducing agent such as $\text{NaBH}(\text{OAc})_3$ to give a compound of formula (g);
- v. reacting the compound of formula (g) with an aniline derivative formula (d) in the presence of a second base and a palladium catalyst to give a compound of Formula I; or the compound of formula (e) is prepared by the following steps:
- vi. reacting a compound of formula (h) with a compound of formula (i) in the presence of a first base in a second organic solvent to give a compound of formula (j);
- vii. reacting the compound of formula (j) with a compound of formula (b) in a second organic solvent in the presence of a first base to give a compound of formula (e);




wherein: R^1 , R^2 , R^3 , R^4 , R^5 , R^{6a} , R^{6b} , n , X and Y are described in claim 1.

14. A method for preparing a compound of claim 1, the method comprising reacting a compound of formula (g)



in which R^4 , R^5 , R^{6a} , R^{6b} , n and X are as defined in claim 1, with an aniline derivative of formula (d)



in which R^1 , R^2 , R^3 and Y are as defined in claim 1, in the presence of a base and a palladium catalyst under conditions such that a compound of Formula (I) is prepared.

15. Use of a compound or pharmaceutically acceptable salt thereof as defined in claim 1 for preparing a medicament for the treatment of autoimmune condition, the inflammatory diseases and/or allergic disorders such as systemic lupus erythematosus (SLE), discoid (cutaneous) lupus, Sjorgens syndrome, Wegners granulomatosis and other vasculitides, idiopathic thrombocytopenic purpura, giant cell arteriosis, glomerulonephritis, chronic transplant rejection, chronic obstructive pulmonary disease, adult respiratory distress syndrome, asthma, severe asthma, ulcerative colitis, Crohn's disease, bronchitis, conjunctivitis, psoriasis, scleroderma, (contact and allergic) dermatitis, allergy, (allergic) rhinitis, allergic rhinoconjunctivitis, autoimmune bullous conditions including pemphigus and pemphigoid, mastocytosis, anaphylaxis, chronic (spontaneous) urticaria, Berger's disease, Evans's syndrome, granulocytopenia, Goodpasture's syndrome, hepatitis, Henoch-Schonlein purpura, multiple sclerosis, immunohaemolytic anaemia,

autoimmune haemolytic anemia, Kawasaki syndrome. which can be treated by inhibition of the SYK enzyme.

16. A compound or pharmaceutically acceptable salt thereof of claim 1, for use in the treatment of rheumatoid arthritis and osteoporosis, osteolytic diseases and osteopenia.

17. A compound or pharmaceutically acceptable salt thereof of claim 1, for use in the treatment of heme malignancies, particularly Non-Hodgkin's Lymphomas including follicular (FL), mantle cell, capsule cell lymphoma, neutropenia, small lymphocytic lymphoma, chronic lymphocytic lymphoma, Burkitt and diffuse large B cell lymphomas and T-cell lymphoma.